To investigate whether targeting the PGD2 pathway has therapeutic potential for AD, we treated a subset of rats (WT and Tg-AD males) with timapiprant (also known as OC000459), a potent and highly selective oral DP2 antagonist. This evidence concerns the gene PTGDR2 and Alzheimer disease.